|
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. |
50.00% |
|
Active specific immunotherapy with supportive measures in the treatment of palliatively nephrectomized, renal adenocarcinoma pat |
100.00% |
|
Activity of a multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen in metastatic renal cell carcinoma (m |
80.00% |
|
Adaptive therapy. |
90.00% |
|
Adjuvant simultaneous mistletoe chemotherapy in breast cancer--influence on immunological parameters, quality of life and tolera |
50.00% |
|
Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins. |
90.00% |
|
Adjuvant vaccination with melanoma antigen pulsed dendritic cells (DCs) in stage III melanoma patients. |
85.00% |
|
Adjuvante simultane Mistel-/Chemotherapie bei Mammakarzinom – Einfluss auf Immunparameter, Lebensqualität und Verträglichkeit |
50.00% |
|
Aging: gene silencing or gene activation? |
|
|
Albarin, Injectable Aloe Vera or Polymannons |
65.00% |
|
Albumin Concentration Controls Cancer |
90.00% |
|
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. |
90.00% |
|
Alternative Cancer Treatment (interview with Dr. Gonzalez by Dr. Mercola) |
80.00% |
|
Amino acid conferred protection against melphalan: comparison of amino acids which reduce melphalan toxicity to murine bone marr |
60.00% |
|
Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach. |
90.00% |
|
An Internet misadventure: bloodroot salve toxicity |
80.00% |
|
An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. |
70.00% |
|
An orally active Amazonian plant extract (BIRM) inhibits prostate cancer growth and metastasis. |
80.00% |
|
An RF hyperthermia electrode which generates no edge effect. |
50.00% |
|
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). |
70.00% |
|
Animal studies on Ukrain |
65.00% |
|
Annonacin, a mono-tetrahydrofuran acetogenin, arrests cancer cells at the G1 phase and causes cytotoxicity in a Bax- and caspase |
50.00% |
|
Anthroposophic health care--different and home-like. |
80.00% |
|
Anti-cancer drugs that target metabolism, is dichloroacetate the new paradigm? |
70.00% |
|
Anti-Cancer Infusions |
60.00% |
|
Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. |
70.00% |
|
Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses? |
60.00% |
|
Antiangiogenic metronomic chemotherapy and hyperthermia in the palliation of advanced cancer. |
90.00% |
|
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. |
80.00% |
|
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. |
80.00% |
|
Anticancer Effect of Dihydroartemisinin (DHA) in a Pancreatic Tumor Model Evaluated by Conventional Methods and Optical Imaging. |
70.00% |
|
Anticancer effects and mechanisms of polysaccharide-K (PSK): implications of cancer immunotherapy. |
80.00% |
|
Antinociceptive effect of ten day administration of Ukrain in mice and interaction of the treatment with morphine |
80.00% |
|
Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort. |
70.00% |
|
Antitumor activity of patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells: In vitro results and cli |
70.00% |
|
Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. |
50.00% |
|
Antitumor effects of the benzophenanthridine alkaloid sanguinarine in a rat syngeneic model of colorectal cancer. |
80.00% |
|
Antitumor properties and modulation of antioxidant enzymes' activity by Aloe vera leaf active principles isolated via supercriti |
80.00% |
|
Artemisinin derivates in the treatment of Cancer |
90.00% |
|
Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glyc |
60.00% |
|
Artesunate combined with vinorelbine plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled |
80.00% |
|
Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemi |
70.00% |
|
Association between serum 25(OH)D and death from prostate cancer. |
70.00% |
|
Attitudes of patients to alternative medicine for cancer treatment. |
80.00% |
|
Bcl-2 overexpression protects human keratinocyte cells from Ukrain-induced apoptosis but not from G2/M arrest. |
60.00% |
|
Be prudent of ketamine in treating resistant depression in patients with cancer. |
80.00% |
|
BET bromodomain inhibition as a therapeutic strategy to target c-Myc |
70.00% |
|
Bevacizumab for recurrent ependymoma. |
80.00% |
|
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal |
50.00% |
|
Bio-Immune therapy according to Professor Thomas Tallberg, a cure for Melanoma? |
97.50% |
|
Bioavailability of sorafenib tablets administered as a liquid suspension. |
30.00% |
|
Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potent |
90.00% |
|
Biophysiological effects of Ukrain therapy in a patient with breast cancer (case report) |
60.00% |
|
Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in--- |
80.00% |
|
Blockade of hedgehog signaling pathway as a therapeutic strategy for pancreatic cancer. |
20.00% |
|
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. |
80.00% |
|
Boswellia |
60.00% |
|
Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, |
90.00% |
|
Boswellia serrata: An Overall Assessment of In Vitro, Preclinical, Pharmacokinetic and Clinical Data. |
70.00% |
|
Boswellic acids: biological actions and molecular targets. |
80.00% |
|
Breast Cancer |
|
|
Breast Cancer Treatment |
|
|
c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of non |
50.00% |
|
Cancer Growth and Its Inhibition in Terms of Coherence |
70.00% |
|
Cancer mortality in six lowest versus six highest elevation jurisdictions in the u.s. |
60.00% |
|
Cancer Prevention |
50.00% |
|
Cancer preventive effect of Morinda citrifolia (Noni). |
70.00% |
|
Cancer Psychotherapy according to Dr. Frederick B Levenson |
76.00% |
|
Cannibalism of live lymphocytes by human metastatic but not primary melanoma cells |
80.00% |
|
Carbon-ion treatment |
50.00% |
|
Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy |
90.00% |
|
CECs, CEPs and CTCs for prediction of response in patients with advanced breast cancer (ABC) receiving metronomic vinorelbine. |
60.00% |
|
Cellular immune suppression in cancer patients and its implication for dendritic cell therapy. |
90.00% |
|
Cellular immune suppression in cancer patients and its implication for dendritic cell therapy. Sub-category: Cell-Based Therapy |
90.00% |
|
Chelidonium majus L. (Ukrain) in the treatment of cancer patients. |
63.33% |
|
Chemopreventive and adjuvant therapeutic potential of pomegranate (Punica granatum) for human breast cancer. |
85.00% |
|
Chemoradiotherapy in malignant glioma: standard of care and future directions. |
50.00% |
|
Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. |
50.00% |
|
Chemotherapy of advanced epithelial cancer--a critical review |
90.00% |
|
Chloroquine and its analogs: a new promise of an old drug for effective and safe cancer therapies. |
70.00% |
|
Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy |
50.00% |
|
Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab.... |
40.00% |
|
Circulating tumor cells in gastrointestinal malignancies: current techniques and clinical implications. |
70.00% |
|
Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer |
50.00% |
|
Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refract |
80.00% |
|
Clinical applications of magnetic nanoparticles for hyperthermia. |
80.00% |
|
Clinical aspects of cancer treatment and new biochemical mechanisms of the drug Ukrain. |
20.00% |
|
CLINICAL EXPERIENCE OF CANCER IMMUNOTHERAPY INTEGRATED WITH OLEIC ACID COMPLEXED WITH DE-GLYCOSYLATED VITAMIN D BINDING PROTEIN |
100.00% |
|
Clinical experience of integrative cancer immunotherapy with GcMAF. |
80.00% |
|
Clinical Investigations on Ukrain |
90.00% |
|
Clinical results of N-acetylcysteine after major hepatic surgery: a review. |
70.00% |
|
Clinical studies of Ukrain in healthy volunteers (phase 1). |
60.00% |
|
Clinical studies of Ukrain in terminal cancer patients (phase II) |
80.00% |
|
Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression. |
70.00% |
|
Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. |
40.00% |
|
Combined therapy with Ukrain and chemotherapy in ovarian cancer (case report) |
60.00% |
|
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. |
90.00% |
|
Comparative evaluation of blood plasma and tumor tissue amino acid pool in radiation or neoadjuvant preoperative therapies.... |
50.00% |
|
Comparative evaluation of the efficiency of various Ukrain doses in the combined treatment of breast cancer. |
65.00% |
|
Comparative in vitro study of the effects of the new antitumor drug Ukrain and several cytostatic agents on the thiol groups in |
50.00% |
